Spiriva Respimat (tiotropium) will be the first long-acting anticholinergic for ASTHMA
December 2015
Spiriva Respimat (tiotropium) will be the first long-acting anticholinergic for ASTHMA. It won't just be for COPD anymore.
But don't expect to see it used first-line for asthma.
Explain that adding Spiriva to a medium-dose inhaled steroid may improve lung function about the same as adding a long-acting beta-agonist (salmeterol, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote